Propiedad y actividad de insiders de LENZ Therapeutics, Inc. (LENZ): operaciones de insiders, transacciones del Senado y la Cámara de EE. UU. y acciones en circulación. Sigue cómo operan la acción los directivos y los políticos.
Precio
| Precio | $4.14 |
| Capitalización | $130M |
| Bolsa | NASDAQ |
| País | US |
Operaciones Recientes de Insiders
| Fecha | Insider | Tipo | Acciones | Valor |
|---|---|---|---|---|
| 2026-06-15 | RA CAPITAL MANAGEMENT, L.P. | A-Award | 22,100 | $147K |
| 2026-06-15 | George Jeffrey P. | A-Award | 22,100 | $147K |
| 2026-06-15 | Drapkin Kimberlee C | A-Award | 22,100 | $147K |
| 2026-06-15 | MCCOLLUM JAMES W | A-Award | 22,100 | $147K |
| 2026-06-15 | Thunen Shelley B | A-Award | 22,100 | $147K |
| 2026-06-15 | Guerard Frederic | A-Award | 22,100 | $147K |
| 2026-06-15 | Scheiner Zachary | A-Award | 22,100 | $147K |
| 2026-03-27 | George Jeffrey P. | P-Purchase | 5,592 | $50K |
| 2026-03-27 | Schimmelpennink Evert B. | P-Purchase | 28,089 | $251K |
| 2026-03-27 | Chevallard Daniel R. | P-Purchase | 7,500 | $64K |
Balance (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Caja y Equivalentes | $6000 | $19.8M | $18.3M | $44.4M | $35.1M | $20.2M | $25.2M |
| Inversiones a Corto | 0 | 0 | 0 | 0 | $30.7M | $188.9M | $267.2M |
| Cuentas por Cobrar | 0 | 0 | 0 | 0 | 0 | 0 | $2.4M |
| Inventario | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Corrientes | $6000 | $21.1M | $18.3M | $46.6M | $67.2M | $211.9M | $301.4M |
| Inmovilizado Material | 0 | $1.5M | $10000 | $279000 | $372000 | $2.0M | $1.9M |
| Fondo de Comercio | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Intangibles | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Totales | $6000 | $22.6M | $18.3M | $47.0M | $70.4M | $215.3M | $305.9M |
| Cuentas por Pagar | 0 | $630000 | $460000 | $4.8M | $5.7M | $4.3M | $4.2M |
| Deuda a Corto | $2.2M | 0 | 0 | 0 | 0 | 0 | 0 |
| Pasivos Corrientes | $2.2M | $32.0M | $1.3M | $9.5M | $18.5M | $10.4M | $21.2M |
| Deuda a Largo | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pasivos Totales | $2.2M | $32.4M | $32.5M | $71.1M | $163.1M | $11.2M | $21.5M |
| Reservas | -$2.2M | -$70.6M | -$14.5M | -$25.3M | -$95.2M | -$145.0M | -$227.1M |
| Patrimonio Neto | -$2.2M | -$9.8M | -$14.2M | -$24.2M | -$92.7M | $204.1M | $284.3M |
| Deuda Total | $2.2M | 0 | 0 | $250000 | $329000 | $1.4M | $815000 |
| Deuda Neta | $2.2M | -$19.8M | -$18.3M | -$44.2M | -$65.5M | -$207.6M | -$291.5M |
| Capital Circulante | -$2.2M | -$10.9M | $17.1M | $37.1M | $48.7M | $201.5M | $280.2M |
Salud financiera
| Deuda / Patrimonio | 0.00 |
| Ratio corriente | 13.55 |
Rentabilidad
| Rentabilidad sobre capital | -53.39% |
| Rentabilidad sobre capital invertido | -61.84% |
| Rentabilidad sobre activos | -53.26% |
| Margen bruto | 90.14% |
| Margen operativo | -631.70% |
| Margen neto | -586.74% |
Empresas relacionadas: ABUS · GERN · GHRS · MRVI · NBTX · PRME · RZLT
Explorar sector: Healthcare · Biotechnology
Más secciones de LENZ: Resumen · Financieros · Valoración · Estadísticas · Estimaciones · Técnico · Noticias · Eventos
Descubre más: Radar — señales de acciones infravaloradas · Academia de Inversión — aprende a analizar acciones